



Kaletra® (lopinavir/ritonavir) – First-time generic

- On June 7, 2021, [Camber launched](#) an [AB-rated](#) generic version of AbbVie's [Kaletra \(lopinavir/ritonavir\)](#) tablets.
- Kaletra is approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older.
- Lopinavir/ritonavir is also available generically as an [oral solution](#) and carries the same indication as Kaletra tablets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.